Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Poziotinib in Japanese NSCLC with EGFR/HER2 exon 20 insertions
jRCT2080225208Phase 2Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of poziotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Spectrum Pharmaceuticals, Inc. Started May 2020; status: terminated.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225208.